Navigation Links
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
Date:9/9/2008

ternal medicine with a subspecialty in endocrinology and metabolism.

"We are very pleased to have Ken join Intarcia Therapeutics to lead our hepatitis C and diabetes clinical development efforts," said Alice Leung. "Ken's drug development experience and expertise in the areas of diabetes and metabolic diseases are tremendous assets as we prepare to initiate clinical development of ITCA 650 for the treatment of type 2 diabetes. We look to his significant clinical and development expertise as we bring Omega DUROS therapy into later stages of development as well as expand the Company's pipeline in the metabolic diseases area."

Intarcia is currently conducting a phase 1 study of Omega DUROS therapy in combination with ribavirin for the treatment of patients with HCV genotype-1 who have failed prior standard of care treatment. In addition, Intarcia is preparing to initiate a phase 1 clinical trial of ITCA 650 in the first quarter of 2009 for the treatment of type 2 diabetes. Both of these programs use Intarcia's proprietary subcutaneous DUROS drug delivery technology that provides continuous and consistent administration of drug therapy.

Dr. Luskey said, "Intarcia represents a very unique opportunity. I believe the proven advantages of the DUROS delivery technology hold great potential in developing more effective treatments for many chronic diseases, including hepatitis C and type 2 diabetes. I am very excited to join Intarcia at this stage of the Company's development and look forward to directing clinical programs to fulfill the potential of DUROS delivery in these two disease areas."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent ma
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Reverse Stock Split
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
7. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
8. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
9. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... Petit, has been awarded the Lifetime Achievement Award in ... The Entrepreneur Of The Year Program, ...
(Date:6/29/2015)... ... 29, 2015 , ... The StampedeCon 2015 Big Data Conference will ... in a row, will bring top technology professionals to St. Louis. Top industry speakers ... data and technology. The event is proudly sponsored by DataStax, Cisco, World Wide Technology, ...
(Date:6/29/2015)... , June 29, 2015 ... medical information products and services, today announced the highlights ... to the 2014 Journal Citation Reports® (JCR) published by ... Factors increase from 2013 to 2014, ahead of the ... the top rank in 62 subject categories, up from ...
(Date:6/26/2015)... , June 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced that all nominees listed in the management ... at its 2015 Annual Meeting of Shareholders, held ... by ballot, the following 5 nominees proposed by ... to serve until the Company,s next Annual Meeting ...
Breaking Biology Technology:EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... WYE ),today announced that its Board of Directors has ... immediately. Mr. Davidson will,continue in his role as Vice ... divisional financial positions since joining the Company,in 1984. These ... Officer, Wyeth Consumer Healthcare and Deputy Treasurer, Wyeth. ...
... Abercrombie, Pfizer R&D Head Martin,Mackay, HHS Deputy Secretary Tevi ... Agenda at FDA/CMS Summit 2007, WASHINGTON, Nov. 15 ... drug approvals. Unfortunately for the biopharma sector and,investors, it,s ... on track,to grant marketing approval to 18 or fewer ...
... MONICA, Calif., Nov. 15 Aida,Pharmaceuticals, Inc. (OTC Bulletin ... 10Q for the period ended September 30, 2007. Net,revenues ... of,5% over the same period in 2006. Gross profit ... Goods Sold. Most notably, sales from Aida,s,transfusion and injection ...
Cached Biology Technology:So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... turned off or left on in healthy ... common cancers and maybe help avoid them, Medical College ... alterations, called DNA methylation, in the body,s basic building ... and their cancerous counterpart to find telltale patterns that ...
... A new study finds that most older long-term cancer survivors ... health habits. The study also reveals that those survivors ... health and quality of life. Published in the September 1, ... the American Cancer Society, the research indicates that greater efforts ...
... The results of a national assessment of indoor location ... announced at Worcester Polytechnic Institute (WPI) during the 2009 ... Emergency Responders, which runs from Aug. 3 to 4. ... with funding from the Department of Homeland Security and ...
Cached Biology News:Cancer's distinctive pattern of gene expression could aid early screening and prevention 2Cancer's distinctive pattern of gene expression could aid early screening and prevention 3Cancer's distinctive pattern of gene expression could aid early screening and prevention 4Most older long-term cancer survivors have poor health habits 2Results of national assessment of first responder location systems to be announced Aug. 3 2Results of national assessment of first responder location systems to be announced Aug. 3 3Results of national assessment of first responder location systems to be announced Aug. 3 4
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Human Rad1 MAb (Clone 33)...
Biology Products: